Similar articles

• Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.

  Komura K, Jeong SH, Hinohara K, Qu F, Wang X, Hiraki M, Azuma H, Lee GS, Kantoff PW, Sweeney CJ. Komura K, et al. Proc Natl Acad Sci U S A. 2016 May 31;113(22):6259-64. doi: 10.1073/pnas.1600420113. Epub 2016 May 16. Proc Natl Acad Sci U S A. 2016. PMID: 27185910 Free PMC article.
• Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer.

  Yoshikawa Y, Stopsack KH, Wang XV, Chen YH, Mazzu YZ, Burton F, Chakraborty G, Rajanala SH, Hirani R, Nandakumar S, Lee GM, Frank D, Davicioni E, Liu G, Carducci MA, Azuma H, Kantoff PW, Sweeney CJ. Yoshikawa Y, et al. Mol Oncol. 2022 Dec;16(22):3994-4010. doi: 10.1002/1878-0261.13314. Epub 2022 Oct 2. Mol Oncol. 2022. PMID: 36087093 Free PMC article.
• ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.

  Komura K, Yoshikawa Y, Shimamura T, Chakraborty G, Gerke TA, Hinohara K, Chadalavada K, Jeong SH, Armenia J, Du SY, Mazzu YZ, Taniguchi K, Ibuki N, Meyer CA, Nanjangud GJ, Inamoto T, Lee GM, Mucci LA, Azuma H, Sweeney CJ, Kantoff PW. Komura K, et al. J Clin Invest. 2018 Jul 2;128(7):2979-2995. doi: 10.1172/JCI96769. Epub 2018 Jun 4. J Clin Invest. 2018. PMID: 29863497 Free PMC article.
• Multiple roles for UDP-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes in androgen metabolism and prostate cancer evolution.

  Gauthier-Landry L, Bélanger A, Barbier O. Gauthier-Landry L, et al. J Steroid Biochem Mol Biol. 2015 Jan;145:187-92. doi: 10.1016/j.jsbmb.2014.05.009. Epub 2014 May 23. J Steroid Biochem Mol Biol. 2015. PMID: 24861263 Review.
• Regulation of androgen receptor signaling in prostate cancer.

  Dehm SM, Tindall DJ. Dehm SM, et al. Expert Rev Anticancer Ther. 2005 Feb;5(1):63-74. doi: 10.1586/14737140.5.1.63. Expert Rev Anticancer Ther. 2005. PMID: 15757439 Review.